Total: $509.87M

Company
(Symbol)#

Type Of Financing

Number
Of
Shares,
Units Or
Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details
(Date)@


AlphaRx
Inc.
(Canada;
OTC BB:
AHRX)

Private placement of common stock and warrants

N/A

$0.5

AlphaRx raised $500,000 through an interim unit financing conducted by Greystone Mercantile Bancorp Ltd. (10/16)

AltaRex
Corp.
(OTC
BB:ALXFF;
TSE:AXO)

Private placement of special units

7.2U

C$12.6
(US$8)

AltaRex raised US$8M in the private placement led by Yorkton Securities Inc.; the syndicate also includes Wells Fargo Van Kasper; each unit entitles the holder to acquire one common share and one warrant to purchase one share at C$2 (10/23)

Arius
Research
Inc.
(Canada; CDNX:YAR)

Rights offering

0.756S

C$2.65 (US$1.7)

Arius raised US$1.7M in a rights offering of 756,000 common shares (10/9)

Avant Immuno-
therapeutics
Inc.
(AVAN)

Private placement of common stock

3S

$14

Avant raised $14M in the sale of 3M shares that were part of a shelf registration filed in July; Ladenburg Thalmann & Co. acted as placement agent (10/17)

Biomira Inc.
(BIOM)

Private placement of convertible debentures and warrants

W for 0.75S

$15

Biomira raised $15M in the private placement; the debentures may be converted into Biomira common shares at holders' options for $6 each, with maturity at 22 months; warrants for 750,000 common shares were issued to the debenture holders at a fixed price of $6, with the term expiring Dec. 31, 2004 (10/1)

Cubist
Pharma-
ceuticals
Inc.
(CBST)

Private placement of subordinated notes

N/A

$125

Cubist raised $125M by offering 5.5%, seven-year subordinated notes, due in 2008 and convertible into Cubist common stock; the notes were sold to institutional buyers (10/23)

Discovery
Laboratories
Inc.
(DSCO)

Private placement of units

U consisting of 3.5S and W for 0.7S

$7.7

Discovery Laboratories completed a private placement, raising about $7.7M; it sold units consisting of about 3.5M shares of common stock and warrants to purchase about 700,000 shares (10/3)

MGI Pharma
Inc.
(MOGN)

Private placement of common stock

3S

$31

MGI Pharma raised $31M in a private placement with institutional investors; U.S. Bancorp Piper Jaffray acted as placement agent (10/31)

Nastech
Pharmaceu-
tical Company
Inc.
(NSTK)

Private placement of common stock

1.1S

$5.8

Nastech raised about $5.8M in a private financing; Dain Rauscher Wessels acted as exclusive placement agent; investors were Safeco Growth and RST Opportunities Fund, MPM Capital BioEquities Fund, Perceptive Life Sciences Fund and RS Investments Growth Fund (10/18)

Organo-
genesis
Inc.
(AMEX:ORG)

Private placement of convertible subordinated notes and common stock

2.17S

$20.25

Organogenesis raised $10M from the sale of 7% convertible subordinated notes to Novartis Pharma AG; it raised an additional $10.25M with the sale of 2.17M shares to institutional investors, directors of the company and other individuals (10/16)

Paradigm
Genetics Inc.
(PDGM)

Private placement of common stock

5.1S

$28

Paradigm Genetics raised $28M through the placement of 5.1M shares at $5.50 per share with JP Morgan H&Q; the deal is pursuant to a $75M shelf registration filed in September (10/17)

ReGen
Therapeutics
plc
(UK; LSE:
RGT)

Private placement of common stock

10.5S

#1 (US
$1.42)

ReGen conditionally placed 10.5M shares at 10 pence each, raising about US$1.42M (10/24**)

Regeneron
Pharma-
ceuticals
Inc.
(REGN)

Private placement of seven-year convertible notes

N/A

$200

Regeneron placed the notes, which will accrue interest at 5.5% annually and have a conversion price of $30.25; purchasers of the stock have an option to buy another $50M in principal amount of notes (10/12)

Siga Tech-
nologies
Inc.
(SIGA)

Private placement of common stock and warrants

0.67S and W for 0.33S

$2

Siga raised $2M in the private placement of 0.67 shares and warrants for another 0.33 shares; the shares and warrants were placed by the Shemano Group (10/12)

Triangle
Pharma-
ceuticals
Inc.
(VIRS)

Private placement of common stock

18.7S

$49.5

Triangle sold 18.7M shares of common stock at $2.65 per share to a group of investors led by Warburg Pincus Private Equity VIII LP; Banc of America Securities LLC served as placement agent; this is the second closing of a financing begun in August (10/11)


Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

** Denotes the date the item ran in BioWorld International.

@ Dates refer to the date of the press release.

N/A = Not available, applicable or reported.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange

No Comments